SAN DIEGO, April 9, 2020 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces that it has verified a COVID-19 molecular
diagnostic test, and plans to begin accepting physician-ordered
testing requests for processing beginning on April 15, 2020.
Biocept has partnered with a national clinician network to
accept patient samples and may obtain additional agreements as test
capacity is increased. Biocept operates a high-complexity,
CLIA-certified, CAP-accredited and BSL-2 safety level laboratory in
San Diego, with specialized,
licensed molecular lab staff that have been trained in performing
the COVID-19 testing. The lab will be using the FDA-approved for
EUA (Emergency Use Authorization) testing ThermoFisher Scientific's
TaqPath™ molecular diagnostic platform and kit for SARS-CoV-2
(COVID-19).
"While we continue to focus primarily on providing actionable
results for patients diagnosed with cancer, we are pleased to
support our clients and public health efforts by expanding our
offerings to include COVID-19 testing. I am very thankful to
our laboratory team for stepping up and quickly validating COVID-19
testing, in addition to the vital work we do each day for patients
diagnosed with cancer," said Mike
Nall, Biocept's Chief Executive Officer. "We will
provide this critical testing to physicians as we fight the global
coronavirus pandemic."
In preparation to offer COVID-19 testing, an unapproved version
of a test website page was inadvertently posted to the Company's
website by a third-party website consultant. This unapproved
test website page contained certain inaccuracies related to billing
matters and should be disregarded.
For physician questions, please contact
customerservice@biocept.com.
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with cancer. The Company's patented Target Selector™
liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
outcomes of patients diagnosed with cancer, the exact time that we
will begin accepting physician-ordered COVID-19 testing requests
for processing, and our ability to enter into additional
agreements to accept COVID-19 patient samples, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
Media Contact:
CORE IR
Jules Abraham
julesa@coreir.com
917-885-7378
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-to-begin-covid-19-testing-301038660.html
SOURCE Biocept, Inc.